

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 21 U.S.C. § 355(n)(4)

Andrew C. Leon, Ph.D.


Committee: Psychopharmacologic Drugs Advisory Committee

Meeting Date: December 2, 2005


I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 21-514, proposed trade name Methypatch (Methylphenidate Transdermal System, MTS), sponsored by Noven Pharmaceuticals, Inc., and Shire Pharmaceutical Group plc, proposed indication for the treatment of Attention Deficit Hyperactivity Disorder, I am eligible to receive a waiver under 21 U.S.C. § 355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued from \$5,001 to \$25,000.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.



Signature of SGE



Date